verticine has been researched along with forsythiaside in 1 studies
| Studies (verticine) | Trials (verticine) | Recent Studies (post-2010) (verticine) | Studies (forsythiaside) | Trials (forsythiaside) | Recent Studies (post-2010) (forsythiaside) |
|---|---|---|---|---|---|
| 63 | 0 | 34 | 119 | 1 | 87 |
| Protein | Taxonomy | verticine (IC50) | forsythiaside (IC50) |
|---|---|---|---|
| Protein kinase C alpha type | Homo sapiens (human) | 1.9 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Du, H; Gong, G; Liu, C; Ma, Q; Quan, ZS; Wu, Y; Zhen, D | 1 |
1 other study(ies) available for verticine and forsythiaside
| Article | Year |
|---|---|
Synergistic anti-inflammatory effects of peimine, peiminine, and forsythoside a combination on LPS-induced acute lung injury by inhibition of the IL-17-NF-κB/MAPK pathway activation.
Topics: Acute Lung Injury; Animals; Anti-Inflammatory Agents; Cevanes; Cytokines; Forsythia; Fritillaria; Glycosides; Interleukin-17; Interleukin-6; Lipopolysaccharides; Lung; Male; Mice; NF-kappa B; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha | 2022 |